Fresenius Medical Care

Retia Medical develops monitors for high-risk patients. Retia’s first product monitors cardiac output, a critical health metric that indicates the flow rate of blood pumped by the heart. The initial target market for this technology is the ICU and perating rooms. It is potentially extendable for use in emergency rooms or at home. Based in East Lansing, MI, Retia’s technology was exclusively licensed from MSU and validated through extensive tests in animals and humans. With the support of the Pritzker/Vlock family office and a strong advisory board composed of industry and clinical experts, Retia will seek FDA approval and launch this product, which will help revolutionize the care of our most at-risk patients.

Memo Therapeutics AG, based in Basel, Switzerland, specializes in antibody discovery and immune repertoire analysis through its innovative MemoMAB platform. This technology enables the creation of a recombinant in vitro copy of an individual’s B cell and antibody repertoire, resulting in unique and extensive libraries that reflect a person's immune response. These libraries are anticipated to contain a significant number of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics employs its MemoMAB platform in proprietary antibody lead discovery programs and offers it for collaboration with other entities, enhancing the potential for novel therapeutic developments.

SafeRide, Inc. is a San Francisco-based company that develops a digital health platform and mobile application designed to facilitate non-emergency medical transport (NEMT) for patients. The platform allows healthcare providers to efficiently book and manage transportation, addressing issues such as appointment no-shows and future scheduling needs. Key features include the ability to send appointment reminders, real-time text alerts, and ride tracking, ensuring patient safety and quality service. SafeRide also offers tools to identify and monitor at-risk patients before they require critical care. Since its founding in 2015, the company has expanded its service network to include major cities such as Los Angeles, Seattle, Portland, St. Louis, and the greater New York area.

Humacyte, Inc. is a medical research and development company headquartered in Morrisville, North Carolina, established in 2004. The company specializes in creating human tissue-based products aimed at regenerative medicine and vascular surgery. Its core technology involves the design of acellular extracellular matrices derived from banked vascular smooth muscle cells, which are decellularized to minimize the risk of rejection. These innovations are utilized to produce tissue-engineered grafts for patients requiring vascular repair or replacement, positioning Humacyte as a key player in addressing vascular diseases and enhancing surgical outcomes.

InterWell Health is a national partnership focused on nephrology, combining the expertise of leading nephrology practices with the resources of Fresenius Medical Care North America. The organization aims to enhance renal healthcare by managing kidney patients through at-risk arrangements with both public and private payors. It addresses the full spectrum of chronic kidney disease, transplant, end-stage renal disease, and conservative care. By promoting value-based contracting models, InterWell Health strives to improve clinical outcomes while reducing costs for renal providers, payors, and patients alike, ultimately enhancing the quality of life for those with kidney-related health issues.

EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.

BioIntelliSense, Inc. specializes in healthcare devices and a data services platform designed for continuous remote health monitoring and predictive analytics. The company offers innovative products such as The BioButton, a wearable medical-grade screening solution aimed at facilitating safe return to work and school, and the BioSticker, a Data-as-a-Service platform that monitors vital signs and symptoms related to COVID-19. Their technology tracks various health metrics, including skin temperature, heart rate, respiratory rate, gait analysis, body position, and activity levels, as well as detecting falls and monitoring sleep patterns. Founded in 2018 and headquartered in Golden, Colorado, BioIntelliSense is committed to delivering algorithmic clinical insights to enhance patient care and health management.

SafeRide, Inc. is a San Francisco-based company that develops a digital health platform and mobile application designed to facilitate non-emergency medical transport (NEMT) for patients. The platform allows healthcare providers to efficiently book and manage transportation, addressing issues such as appointment no-shows and future scheduling needs. Key features include the ability to send appointment reminders, real-time text alerts, and ride tracking, ensuring patient safety and quality service. SafeRide also offers tools to identify and monitor at-risk patients before they require critical care. Since its founding in 2015, the company has expanded its service network to include major cities such as Los Angeles, Seattle, Portland, St. Louis, and the greater New York area.

Modulim develops and manufactures non-invasive optical imaging solutions aimed at assessing tissue health. The company's flagship product, Clarifi, is a non-contact device that measures critical hemoglobin biomarkers in tissue, including tissue oxygen saturation and the concentration and distribution of hemoglobin in both the superficial and sub-surface dermis. Utilizing an advanced technique known as spatial frequency domain imaging (SFDI), Modulim's technology is particularly effective in applications related to diabetic foot ulcers, pressure ulcers, reconstructive surgical flaps, and burns. Founded in 2005 and based in Irvine, California, Modulim is recognized for its innovative approach to identifying patients at risk of complications, enabling clinicians to provide timely interventions that can significantly improve patient outcomes.

Tridiuum, Inc. develops and operates software-as-a-service platform to support behavioral health providers, patients, and health systems across the continuum of care. It offers Tridiuum1, a cloud-based behavioral health outcomes management platform that provides results for monitoring a patient’s symptoms and progress during treatment; and helps health systems and primary care medical groups improve patient experience and outcomes. The company was founded in 1997 and is based in Philadelphia, Pennsylvania.

Vectorious Medical Technologies Ltd., a medical device company, develops and manufactures cardiac monitoring system for patients suffering from congestive heart failure. It offers a monitoring system for congestive heart failure patients based on a miniature wireless implant to enable daily push button readings of left atrial pressure. The company was founded in 2011 and is based in Tel Aviv, Israel.

Humacyte, Inc. is a medical research and development company headquartered in Morrisville, North Carolina, established in 2004. The company specializes in creating human tissue-based products aimed at regenerative medicine and vascular surgery. Its core technology involves the design of acellular extracellular matrices derived from banked vascular smooth muscle cells, which are decellularized to minimize the risk of rejection. These innovations are utilized to produce tissue-engineered grafts for patients requiring vascular repair or replacement, positioning Humacyte as a key player in addressing vascular diseases and enhancing surgical outcomes.

Vectorious Medical Technologies Ltd., a medical device company, develops and manufactures cardiac monitoring system for patients suffering from congestive heart failure. It offers a monitoring system for congestive heart failure patients based on a miniature wireless implant to enable daily push button readings of left atrial pressure. The company was founded in 2011 and is based in Tel Aviv, Israel.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.

Modulim develops and manufactures non-invasive optical imaging solutions aimed at assessing tissue health. The company's flagship product, Clarifi, is a non-contact device that measures critical hemoglobin biomarkers in tissue, including tissue oxygen saturation and the concentration and distribution of hemoglobin in both the superficial and sub-surface dermis. Utilizing an advanced technique known as spatial frequency domain imaging (SFDI), Modulim's technology is particularly effective in applications related to diabetic foot ulcers, pressure ulcers, reconstructive surgical flaps, and burns. Founded in 2005 and based in Irvine, California, Modulim is recognized for its innovative approach to identifying patients at risk of complications, enabling clinicians to provide timely interventions that can significantly improve patient outcomes.

NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its primary product includes the NxStage System One (the System One). NxStage operates in two segments: System One and In-Center. The Company markets the System One to hospitals for treatment of acute kidney failure and fluid overload. In addition to the System One, NxStage sells a line of extracorporeal disposable products for use primarily for in-center dialysis treatments for patients with end-stage renal disease (ESRD). These products, which consist of Medisystems, include hemodialysis blood tubing sets, A.V. fistula needles and apheresis needles. The Company's blood tubing set products include the ReadySet High Performance Blood Tubing set (ReadySet), and the Streamline Airless Blood Tubing set (Streamline).

Cura Day Hospitals Group was established in 2008 and has grown to become Australia's leading provider of day hospital facilities.

XENiOS AG specializes in developing medical devices aimed at treating acute and chronic lung failure, as well as cardiac insufficiency. The company's product range includes the iLA active platform, which offers solutions for pumped extrapulmonary lung support, along with various kits and devices such as the NovaTherm Heater/Cooler for blood temperature management and the iLA Membrane Ventilator for pumpless lung support. Additionally, XENiOS provides a variety of cannulas, pumps, and oxygenators designed for cardiopulmonary bypass and other cardiac applications. The company also focuses on minimally invasive therapies that address both lung and heart conditions on a single platform, differentiating itself in the market. Founded in 2013 and based in Heilbronn, Germany, XENiOS AG is a subsidiary of Fresenius Medical Care AG & Co. KGaA and offers comprehensive clinical application support, technical training, and customer service to healthcare professionals.

Sparsh Nephrocare focuses on making dialysis treatment accessible to kidney failure patients throughout India and South East Asia. It operates in-hospital dialysis units and standalone dialysis therapy centers, utilizing advanced machines and employing well-trained technicians. The company has introduced innovative concepts such as the in-hospital dialysis center and has established dialysis facilities through Public Private Partnership (PPP) models with leading government institutions. By managing the complete operations of these centers and ensuring that all medical records are stored electronically in compliance with NABH norms, Sparsh Nephrocare aims to alleviate the operational burdens faced by hospital management. The organization is committed to creating a comprehensive ecosystem that enhances the accessibility and quality of renal care for patients in the region.

National Cardiovascular Partners is an operator of endovascular, vascular and cardiovascular services in the comfort and convenience of the outpatient setting. In partnership with over 200 physicians, NCP operates 21 outpatient vascular centers in six states.

Sound Physicians is a provider of inpatient physician services focused on enhancing the quality and satisfaction of healthcare for its hospital partners. Founded and managed by physicians, the company employs over 1,000 hospitalist and post-acute care physicians who deliver care in more than 70 hospitals and a growing number of post-acute care centers across the United States. Sound Physicians offers a comprehensive range of services, including emergency medicine, critical care, hospital medicine, population health, telemedicine, and physician advisory services. By partnering closely with healthcare providers, the company aims to improve both clinical outcomes and financial performance within healthcare systems.

ApolloMed is a physician-driven, integrated population health management company at the forefront of the U.S. movement towards value-based care. We manage the treatment of Medicare, Medicaid, and Commercial patients under risk-based contracts with payors. Our coordinated services improve patient quality of life, enhance patients’ care experience, and reduce utilization and costs of healthcare. ApolloMed provides care to its members through both contracted physicians and a network of ancillary support services, such as urgent care centers, surgery centers, imaging, lab services, and more.

Liberty Dialysis, LLC, along with its affiliates, develops, owns, and operates dialysis clinics in the United States. It offers chronic kidney disease outreach and home dialysis programs. The company was founded in 2002 and is based in Mercer Island, Washington. It has clinic locations in Alaska, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Indiana, Maryland, Michigan, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Texas, Utah, Virginia, West Virginia, and Wisconsin. As of February 28, 2012, Liberty Dialysis, LLC operates as a subsidiary of Fresenius Medical Care AG & Co. KGAA.

American Access Care is a hospital & health care company that provides dialysis access management services.

Renal Advantage Inc. (RAI) is a Brentwood TN based provider of outpatient dialysis services. Founded by veteran health care executives, they operate more than 154 freestanding renal dialysis centers. Their Center-Centric operating philosophy allows them to provide the best experiences for both their patients and healthcare professionals.

Hema Metrics is a medical monitoring devices company. Hema Metrics serves thousands of patients worldwide and provides products for more than 1 million treatments each year.

Renal Solutions is focused on the development of dialysis products and services. Renal Solutions was acquired by Fresenius Medical Care in November 2007. Renal Solutions was founded in 2000 and is based in Warrendale, Pennsylvania.

Jiate Excelsior Co., Ltd. provides dialysis services for treating hemodialysis patients.

Renal Care Group, Inc. provides dialysis services to patients with chronic kidney failure, also known as end-stage renal disease (ESRD). It provides its services for the treatment of chronic and acute renal diseases. The company also provides ancillary service, which is the administration of erythropoietin, also known as Epogen, a bioengineered protein that stimulates the production of red blood cells. As of December 31, 2005, Renal Care Group operated 456 outpatient dialysis centers in 34 states with 7,894 certified dialysis stations and provided inpatient dialysis services to approximately 200 acute care hospitals. The company was founded in 1996 and is headquartered in Nashville, Tennessee. As of March 31, 2006, Renal Care Group, Inc. is a subsidiary of Fresenius Medical Care AG & Co. KGAA.